APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Cancer Antibody Drug Conjugates

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Cancer Antibody Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173974190320 December 2025191 pages

Choose your research edition.

Industry ResearchCancer Antibody Drug Conjugates Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Cancer Antibody Drug Conjugates Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Cancer Antibody Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cancer Antibody Drug Conjugates Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Cancer Antibody Drug Conjugates Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Cancer Antibody Drug Conjugates market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Cancer Antibody Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cancer Antibody Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cancer Antibody Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Cancer Antibody Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, Viventia Biotechnologies, UCB, Stem CentRx, Seattle Genetics and Progenics Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cancer Antibody Drug Conjugates market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cancer Antibody Drug Conjugates and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cancer Antibody Drug Conjugates sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cancer Antibody Drug Conjugates market size, projected growth trends, production technologies, key applications, and end-use industries.

Cancer Antibody Drug Conjugates Segment by Company

Novartis

Merck

Roche

AbbVie

Viventia Biotechnologies

UCB

Stem CentRx

Seattle Genetics

Progenics Pharmaceuticals

PDL BioPharma

Nordic Nanovector

Millennium

Helix BioPharma

Bristol-Myers Squibb

Biotest AG

Biogen Idec

AbGenomics Corporation

Cancer Antibody Drug Conjugates Segment by Type

First & Second Generation ADCs

Third Generation ADCs

Cancer Antibody Drug Conjugates Segment by Application

Hospitals

Clinics

Others

Cancer Antibody Drug Conjugates Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Antibody Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cancer Antibody Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Antibody Drug Conjugates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cancer Antibody Drug Conjugates market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cancer Antibody Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Cancer Antibody Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Cancer Antibody Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Cancer Antibody Drug Conjugates Industry Trends Table 2. Cancer Antibody Drug Conjugates Industry Drivers Table 3. Cancer Antibody Drug Conjugates Industry Opportunities and Challenges Table 4. Cancer Antibody Drug Conjugates Industry Restraints Table 5. Global Cancer Antibody Drug Conjugates Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Cancer Antibody Drug Conjugates Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Cancer Antibody Drug Conjugates Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers Table 9. Global Cancer Antibody Drug Conjugates Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Cancer Antibody Drug Conjugates Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Cancer Antibody Drug Conjugates Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Cancer Antibody Drug Conjugates Manufacturers, Product Type & Application Table 13. Global Cancer Antibody Drug Conjugates Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Cancer Antibody Drug Conjugates by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of First & Second Generation ADCs Table 17. Major Manufacturers of Third Generation ADCs Table 18. Global Cancer Antibody Drug Conjugates Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Cancer Antibody Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 20. Global Cancer Antibody Drug Conjugates Sales by Type (2027-2032) & (K Units) Table 21. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2021-2026) Table 22. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2027-2032) Table 23. Global Cancer Antibody Drug Conjugates Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Cancer Antibody Drug Conjugates Revenue by Type (2021-2026) & (K Units) Table 25. Global Cancer Antibody Drug Conjugates Revenue by Type (2027-2032) & (K Units) Table 26. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2021-2026) Table 27. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Clinics Table 30. Major Manufacturers of Others Table 31. Global Cancer Antibody Drug Conjugates Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Cancer Antibody Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 33. Global Cancer Antibody Drug Conjugates Sales by Application (2027-2032) & (K Units) Table 34. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2021-2026) Table 35. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2027-2032) Table 36. Global Cancer Antibody Drug Conjugates Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Cancer Antibody Drug Conjugates Revenue by Application (2021-2026) & (K Units) Table 38. Global Cancer Antibody Drug Conjugates Revenue by Application (2027-2032) & (K Units) Table 39. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2021-2026) Table 40. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2027-2032) Table 41. Global Cancer Antibody Drug Conjugates Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Cancer Antibody Drug Conjugates Sales by Region (2021-2026) & (K Units) Table 43. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2021-2026) Table 44. Global Cancer Antibody Drug Conjugates Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Cancer Antibody Drug Conjugates Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 48. North America Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 49. Europe Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 51. Europe Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2027-2032) & (K Units) Table 58. Global Cancer Antibody Drug Conjugates Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Cancer Antibody Drug Conjugates Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Cancer Antibody Drug Conjugates Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2021-2026) Table 62. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2027-2032) Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Novartis Cancer Antibody Drug Conjugates Product Portfolio Table 67. Novartis Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Merck Cancer Antibody Drug Conjugates Product Portfolio Table 72. Merck Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Roche Cancer Antibody Drug Conjugates Product Portfolio Table 77. Roche Recent Development Table 78. AbbVie Company Information Table 79. AbbVie Business Overview Table 80. AbbVie Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. AbbVie Cancer Antibody Drug Conjugates Product Portfolio Table 82. AbbVie Recent Development Table 83. Viventia Biotechnologies Company Information Table 84. Viventia Biotechnologies Business Overview Table 85. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Portfolio Table 87. Viventia Biotechnologies Recent Development Table 88. UCB Company Information Table 89. UCB Business Overview Table 90. UCB Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. UCB Cancer Antibody Drug Conjugates Product Portfolio Table 92. UCB Recent Development Table 93. Stem CentRx Company Information Table 94. Stem CentRx Business Overview Table 95. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Stem CentRx Cancer Antibody Drug Conjugates Product Portfolio Table 97. Stem CentRx Recent Development Table 98. Seattle Genetics Company Information Table 99. Seattle Genetics Business Overview Table 100. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Seattle Genetics Cancer Antibody Drug Conjugates Product Portfolio Table 102. Seattle Genetics Recent Development Table 103. Progenics Pharmaceuticals Company Information Table 104. Progenics Pharmaceuticals Business Overview Table 105. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Portfolio Table 107. Progenics Pharmaceuticals Recent Development Table 108. PDL BioPharma Company Information Table 109. PDL BioPharma Business Overview Table 110. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. PDL BioPharma Cancer Antibody Drug Conjugates Product Portfolio Table 112. PDL BioPharma Recent Development Table 113. Nordic Nanovector Company Information Table 114. Nordic Nanovector Business Overview Table 115. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Nordic Nanovector Cancer Antibody Drug Conjugates Product Portfolio Table 117. Nordic Nanovector Recent Development Table 118. Millennium Company Information Table 119. Millennium Business Overview Table 120. Millennium Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Millennium Cancer Antibody Drug Conjugates Product Portfolio Table 122. Millennium Recent Development Table 123. Helix BioPharma Company Information Table 124. Helix BioPharma Business Overview Table 125. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Helix BioPharma Cancer Antibody Drug Conjugates Product Portfolio Table 127. Helix BioPharma Recent Development Table 128. Bristol-Myers Squibb Company Information Table 129. Bristol-Myers Squibb Business Overview Table 130. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Portfolio Table 132. Bristol-Myers Squibb Recent Development Table 133. Biotest AG Company Information Table 134. Biotest AG Business Overview Table 135. Biotest AG Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Biotest AG Cancer Antibody Drug Conjugates Product Portfolio Table 137. Biotest AG Recent Development Table 138. Biogen Idec Company Information Table 139. Biogen Idec Business Overview Table 140. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Biogen Idec Cancer Antibody Drug Conjugates Product Portfolio Table 142. Biogen Idec Recent Development Table 143. AbGenomics Corporation Company Information Table 144. AbGenomics Corporation Business Overview Table 145. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. AbGenomics Corporation Cancer Antibody Drug Conjugates Product Portfolio Table 147. AbGenomics Corporation Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Cancer Antibody Drug Conjugates Distributors List Table 151. Cancer Antibody Drug Conjugates Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Cancer Antibody Drug Conjugates Product Image Figure 2. Global Cancer Antibody Drug Conjugates Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cancer Antibody Drug Conjugates Market Size (2021-2032) & (US$ Million) Figure 4. Global Cancer Antibody Drug Conjugates Sales (2021-2032) & (K Units) Figure 5. Global Cancer Antibody Drug Conjugates Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Cancer Antibody Drug Conjugates Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. First & Second Generation ADCs Image Figure 9. Third Generation ADCs Image Figure 10. Global Cancer Antibody Drug Conjugates Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Cancer Antibody Drug Conjugates Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2021-2032) Figure 13. Global Cancer Antibody Drug Conjugates Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Cancer Antibody Drug Conjugates Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Clinics Image Figure 18. Others Image Figure 19. Global Cancer Antibody Drug Conjugates Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Cancer Antibody Drug Conjugates Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2021-2032) Figure 22. Global Cancer Antibody Drug Conjugates Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Cancer Antibody Drug Conjugates Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2021-2032) Figure 25. North America Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 27. U.S. Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 32. Germany Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 39. China Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share by Country (2021-2032) Figure 47. Brazil Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Cancer Antibody Drug Conjugates Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Cancer Antibody Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 58. North America Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Cancer Antibody Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 60. Europe Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Cancer Antibody Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Cancer Antibody Drug Conjugates Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Cancer Antibody Drug Conjugates Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Cancer Antibody Drug Conjugates Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • First & Second Generation ADCs
  • Third Generation ADCs
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Novartis
  • Merck
  • Roche
  • AbbVie
  • Viventia Biotechnologies
  • UCB
  • Stem CentRx
  • Seattle Genetics
  • Progenics Pharmaceuticals
  • PDL BioPharma
  • Nordic Nanovector
  • Millennium
  • Helix BioPharma
  • Bristol-Myers Squibb
  • Biotest AG
  • Biogen Idec
  • AbGenomics Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cancer Antibody Drug Conjugates Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cancer Antibody Drug Conjugates Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Cancer Antibody Drug Conjugates Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Cancer Antibody Drug Conjugates Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Cancer Antibody Drug Conjugates Market Dynamics
  1. 2.1 Cancer Antibody Drug Conjugates Industry Trends
  2. 2.2 Cancer Antibody Drug Conjugates Industry Drivers
  3. 2.3 Cancer Antibody Drug Conjugates Industry Opportunities and Challenges
  4. 2.4 Cancer Antibody Drug Conjugates Industry Restraints
3 Cancer Antibody Drug Conjugates Market by Manufacturers
  1. 3.1 Global Cancer Antibody Drug Conjugates Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Cancer Antibody Drug Conjugates Sales by Manufacturers (2021-2026)
  3. 3.3 Global Cancer Antibody Drug Conjugates Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Cancer Antibody Drug Conjugates Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Cancer Antibody Drug Conjugates Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Cancer Antibody Drug Conjugates Manufacturers, Product Type & Application
  7. 3.7 Global Cancer Antibody Drug Conjugates Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Cancer Antibody Drug Conjugates Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Cancer Antibody Drug Conjugates Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Cancer Antibody Drug Conjugates Tier 1, Tier 2, and Tier 3
4 Cancer Antibody Drug Conjugates Market by Type
  1. 4.1 Cancer Antibody Drug Conjugates Type Introduction
  2. 4.1.1 First & Second Generation ADCs
  3. 4.1.2 Third Generation ADCs
  4. 4.2 Global Cancer Antibody Drug Conjugates Sales by Type
  5. 4.2.1 Global Cancer Antibody Drug Conjugates Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cancer Antibody Drug Conjugates Sales by Type (2021-2032)
  7. 4.2.3 Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2021-2032)
  8. 4.3 Global Cancer Antibody Drug Conjugates Revenue by Type
  9. 4.3.1 Global Cancer Antibody Drug Conjugates Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Cancer Antibody Drug Conjugates Revenue by Type (2021-2032)
  11. 4.3.3 Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2021-2032)
5 Cancer Antibody Drug Conjugates Market by Application
  1. 5.1 Cancer Antibody Drug Conjugates Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Cancer Antibody Drug Conjugates Sales by Application
  6. 5.2.1 Global Cancer Antibody Drug Conjugates Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cancer Antibody Drug Conjugates Sales by Application (2021-2032)
  8. 5.2.3 Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2021-2032)
  9. 5.3 Global Cancer Antibody Drug Conjugates Revenue by Application
  10. 5.3.1 Global Cancer Antibody Drug Conjugates Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cancer Antibody Drug Conjugates Revenue by Application (2021-2032)
  12. 5.3.3 Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2021-2032)
6 Global Cancer Antibody Drug Conjugates Sales by Region
  1. 6.1 Global Cancer Antibody Drug Conjugates Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cancer Antibody Drug Conjugates Sales by Region (2021-2032)
  3. 6.2.1 Global Cancer Antibody Drug Conjugates Sales by Region (2021-2026)
  4. 6.2.2 Global Cancer Antibody Drug Conjugates Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Cancer Antibody Drug Conjugates Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Cancer Antibody Drug Conjugates Revenue by Region
  1. 7.1 Global Cancer Antibody Drug Conjugates Revenue by Region
  2. 7.1.1 Global Cancer Antibody Drug Conjugates Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Cancer Antibody Drug Conjugates Revenue by Region (2021-2026)
  4. 7.1.3 Global Cancer Antibody Drug Conjugates Revenue by Region (2027-2032)
  5. 7.1.4 Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Cancer Antibody Drug Conjugates Revenue (2021-2032)
  8. 7.2.2 North America Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Cancer Antibody Drug Conjugates Revenue (2021-2032)
  11. 7.3.2 Europe Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Cancer Antibody Drug Conjugates Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Cancer Antibody Drug Conjugates Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Cancer Antibody Drug Conjugates Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Cancer Antibody Drug Conjugates Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Cancer Antibody Drug Conjugates Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Cancer Antibody Drug Conjugates Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Cancer Antibody Drug Conjugates Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Viventia Biotechnologies
  26. 8.5.1 Viventia Biotechnologies Company Information
  27. 8.5.2 Viventia Biotechnologies Business Overview
  28. 8.5.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Portfolio
  30. 8.5.5 Viventia Biotechnologies Recent Developments
  31. 8.6 UCB
  32. 8.6.1 UCB Company Information
  33. 8.6.2 UCB Business Overview
  34. 8.6.3 UCB Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 UCB Cancer Antibody Drug Conjugates Product Portfolio
  36. 8.6.5 UCB Recent Developments
  37. 8.7 Stem CentRx
  38. 8.7.1 Stem CentRx Company Information
  39. 8.7.2 Stem CentRx Business Overview
  40. 8.7.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Stem CentRx Cancer Antibody Drug Conjugates Product Portfolio
  42. 8.7.5 Stem CentRx Recent Developments
  43. 8.8 Seattle Genetics
  44. 8.8.1 Seattle Genetics Company Information
  45. 8.8.2 Seattle Genetics Business Overview
  46. 8.8.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Seattle Genetics Cancer Antibody Drug Conjugates Product Portfolio
  48. 8.8.5 Seattle Genetics Recent Developments
  49. 8.9 Progenics Pharmaceuticals
  50. 8.9.1 Progenics Pharmaceuticals Company Information
  51. 8.9.2 Progenics Pharmaceuticals Business Overview
  52. 8.9.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Portfolio
  54. 8.9.5 Progenics Pharmaceuticals Recent Developments
  55. 8.10 PDL BioPharma
  56. 8.10.1 PDL BioPharma Company Information
  57. 8.10.2 PDL BioPharma Business Overview
  58. 8.10.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PDL BioPharma Cancer Antibody Drug Conjugates Product Portfolio
  60. 8.10.5 PDL BioPharma Recent Developments
  61. 8.11 Nordic Nanovector
  62. 8.11.1 Nordic Nanovector Company Information
  63. 8.11.2 Nordic Nanovector Business Overview
  64. 8.11.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nordic Nanovector Cancer Antibody Drug Conjugates Product Portfolio
  66. 8.11.5 Nordic Nanovector Recent Developments
  67. 8.12 Millennium
  68. 8.12.1 Millennium Company Information
  69. 8.12.2 Millennium Business Overview
  70. 8.12.3 Millennium Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Millennium Cancer Antibody Drug Conjugates Product Portfolio
  72. 8.12.5 Millennium Recent Developments
  73. 8.13 Helix BioPharma
  74. 8.13.1 Helix BioPharma Company Information
  75. 8.13.2 Helix BioPharma Business Overview
  76. 8.13.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Helix BioPharma Cancer Antibody Drug Conjugates Product Portfolio
  78. 8.13.5 Helix BioPharma Recent Developments
  79. 8.14 Bristol-Myers Squibb
  80. 8.14.1 Bristol-Myers Squibb Company Information
  81. 8.14.2 Bristol-Myers Squibb Business Overview
  82. 8.14.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb Recent Developments
  85. 8.15 Biotest AG
  86. 8.15.1 Biotest AG Company Information
  87. 8.15.2 Biotest AG Business Overview
  88. 8.15.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Biotest AG Cancer Antibody Drug Conjugates Product Portfolio
  90. 8.15.5 Biotest AG Recent Developments
  91. 8.16 Biogen Idec
  92. 8.16.1 Biogen Idec Company Information
  93. 8.16.2 Biogen Idec Business Overview
  94. 8.16.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Biogen Idec Cancer Antibody Drug Conjugates Product Portfolio
  96. 8.16.5 Biogen Idec Recent Developments
  97. 8.17 AbGenomics Corporation
  98. 8.17.1 AbGenomics Corporation Company Information
  99. 8.17.2 AbGenomics Corporation Business Overview
  100. 8.17.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Product Portfolio
  102. 8.17.5 AbGenomics Corporation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cancer Antibody Drug Conjugates Value Chain Analysis
  2. 9.1.1 Cancer Antibody Drug Conjugates Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cancer Antibody Drug Conjugates Production Mode & Process
  6. 9.2 Cancer Antibody Drug Conjugates Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cancer Antibody Drug Conjugates Distributors
  9. 9.2.3 Cancer Antibody Drug Conjugates Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst